Arrowhead Pharmaceuticals Secures Nearly $900M in Concurrent Equity and 0% Convertible Note Offerings

summarizeSummary

Arrowhead Pharmaceuticals successfully priced concurrent public offerings, raising approximately $897.9 million through common stock, pre-funded warrants, and 0.00% convertible senior notes, significantly bolstering its financial runway.

check_boxKey Events · Financing and Capital Events · ARWR

• Equity Offering Priced

  The company issued 3,100,776 shares of common stock and pre-funded warrants for 1,550,387 shares at public offering prices of $64.50 and $64.499, respectively. This offering, including the full exercise of the underwriters' option for an additional 456,116 shares, is expected to generate approximately $216.6 million in net proceeds.

• 0% Convertible Notes Offering

  Arrowhead priced $625 million aggregate principal amount of 0.00% convertible senior notes due 2032. With the full exercise of the underwriters' option for an additional $75 million, this offering is expected to yield approximately $681.3 million in net proceeds.

• Favorable Note Terms

  The convertible notes bear a 0.00% interest rate and have an initial conversion price of approximately $87.07 per share, representing a 35.0% premium over the common stock offering price. Capped call transactions were also entered into to mitigate potential dilution from note conversions, with a cap price of approximately $119.33 per share (85.0% premium).

• Significant Capital Infusion

  The combined net proceeds from both offerings are estimated to be approximately $897.9 million, providing substantial capital for general corporate purposes, including working capital, capital expenditures, research and development, clinical trials, and potential commercialization activities.

auto_awesomeAnalysis · ARWR · Life Sciences

This substantial capital raise provides Arrowhead Pharmaceuticals with approximately $897.9 million in net proceeds, significantly strengthening its balance sheet and funding future operations. The concurrent offerings, comprising common stock, pre-funded warrants, and 0.00% convertible senior notes, demonstrate strong investor confidence. The convertible notes, with a 0.00% interest rate and a 35% conversion premium, coupled with capped call transactions, are particularly favorable, minimizing immediate dilution while providing substantial long-term capital. This financing is crucial for advancing the company's research and development, clinical trials, and potential commercialization activities for its late-stage products.